相似文献
1
Completing the Translation.
Oncologist. 2020 Mar;25(3):183-185. doi: 10.1634/theoncologist.2019-0650. Epub 2019 Oct 16.
2
The Sequencing Quality Control 2 study: establishing community standards for sequencing in precision medicine.
Genome Biol. 2021 Nov 8;22(1):306. doi: 10.1186/s13059-021-02528-3.
3
Clinical testing should be individualized, not based on populations.
J Clin Invest. 2019 Sep 3;129(9):3472-3473. doi: 10.1172/JCI130903.
4
Circulating tumor DNA for personalized lung cancer monitoring.
BMC Med. 2017 Aug 17;15(1):157. doi: 10.1186/s12916-017-0921-6.
5
[Clinical Utility of Circulating Tumor DNA Analysis for Precision Medicine in Patients with Advanced Gastrointestinal Cancer].
Gan To Kagaku Ryoho. 2021 Oct;48(10):1191-1196.
6
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
JAMA Oncol. 2019 Dec 1;5(12):1710-1717. doi: 10.1001/jamaoncol.2019.3616.
7
Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Lung Cancer. 2017 Sep;111:135-138. doi: 10.1016/j.lungcan.2017.06.015. Epub 2017 Jun 23.
8
Precision Monitoring by Next-Generation Sequencing in Lymphoma: Circulating Tumor DNA as a New Biomarker.
Oncology (Williston Park). 2016 Aug;30(8):745-6.
9
Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy.
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818801809. doi: 10.1177/1533033818801809.
10
[Precision Medicine for Advanced Solid Malignancies Based on Circulating Tumor DNA Analysis].
Gan To Kagaku Ryoho. 2020 Dec;47(12):1645-1652.
本文引用的文献
1
Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance.
JCO Precis Oncol. 2019 Dec;3:1-9. doi: 10.1200/PO.18.00191.
2
Does Testing Error Underlie Liquid Biopsy Discordance?
JCO Precis Oncol. 2019 Dec;3:1-3. doi: 10.1200/PO.18.00408.
3
From Somatic Variants Toward Precision Oncology: An Investigation of Reporting Practice for Next-Generation Sequencing-Based Circulating Tumor DNA Analysis.
Oncologist. 2020 Mar;25(3):218-228. doi: 10.1634/theoncologist.2019-0239. Epub 2019 Aug 30.
4
The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer.
Front Oncol. 2019 Mar 5;9:129. doi: 10.3389/fonc.2019.00129. eCollection 2019.
5
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6.
6
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors.
JAMA Oncol. 2018 Nov 1;4(11):1589-1593. doi: 10.1001/jamaoncol.2018.2297.
7
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.
Clin Cancer Res. 2018 Sep 15;24(18):4437-4443. doi: 10.1158/1078-0432.CCR-18-0143. Epub 2018 Mar 22.
8
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5.
9
Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests.
JAMA Oncol. 2018 Jun 1;4(6):868-870. doi: 10.1001/jamaoncol.2017.4027.
10
Clinical applications of urinary cell-free DNA in cancer: current insights and promising future.
Am J Cancer Res. 2017 Nov 1;7(11):2318-2332. eCollection 2017.
Zotero 插件